Avancerad sökning
Visar resultat 6 - 10 av 342 avhandlingar som matchar ovanstående sökkriterier.
6. Restoring antitumor immunity with dendritic cell reprogramming strategies. Reprogramming cancer cells to antigen-presenting cells
Sammanfattning : For the past two decades, immunotherapy revolutionized cancer treatment. However, responses vary significantly among eligible patients and some cancer types are not yet open to immunotherapy. Several mechanisms contribute to immunotherapy resistance, including loss of antigen presentation machinery and immunosuppression. LÄS MER
7. Dissection of the tonsillar cancer immune microenvironment : Perspectives of the myeloid APC – T-cell axis
Sammanfattning : Tonsillar cancer (TC) is a subset of head and neck cancer (HNC). TC incidence is sharply rising due to an increased prevalence of human papillomavirus (HPV) infection in the western world. Currently HPV status is considered during clinical staging due to its positive association to patient prognosis. LÄS MER
8. Cytomegalovirus Infection in Immunocompetent and Renal Transplant Patients : Clinical Aspects and T-cell Specific Immunity
Sammanfattning : Cytomegalovirus (CMV) is a β-herpesvirus that, after primary infection, establishes a life-long persistence in the human host. Up to 90% of humans are infected with CMV, that is kept under control by CMV-specific CD8+ and CD4+ T cells. In patients with an impaired cellular immunity, however, CMV infections can be life-threatening. LÄS MER
9. Defining the role of CD47 and SIRPα in murine B cell homeostasis
Sammanfattning : B cell development is a highly organized process, which commences in the fetal liver during embryogenesis and in the bone marrow (BM) after birth. Surface IgM+ immature B cells emigrate from the BM via the blood stream to the spleen and finally differentiate into conventional mature follicular B (FoB) cells and marginal zone (MZ) B cells. LÄS MER
10. Hsp70 in immunotherapy : a potential vector in cancer and viral vaccines
Sammanfattning : New efficient vaccines against cancers and infectious diseases are in demand. In 1993 heat shock protein 70 (hsp70) purified from tumour was shown to elicit tumour protection in mice. It was also shown that the protection was not mediated by the hsp70 itself, but by tumour-specific peptides bound to the molecule. LÄS MER